Summit shows mixed results from key study of lung cancer drug

What's new in pharma

May 30, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Wikimedia Commons STAT+ | Summit shows mixed results from key study of lung cancer drug Ivonescimab, which had been previously tested in China, has been closely tracked for its blockbuster potential. By Adam Feuerstein STAT+ | Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials The drug led to a reduction in exacerbations in one study, but missed the mark in another. The companies said they are reviewing the data. By Andrew Joseph STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Adobe STAT+ | Medicare plots ambitious tech agenda guided by former Palantir, Main Street Health executives Medicare wants a tech upgrade to address difficulties patients face in accessing care, and stimulate innovations across industry. By Mario Aguilar

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser